Insights into EPR Effect versus Lectin‐mediated Targeted Delivery: Biodegradable Polycarbonate Micellar Nanoparticles with and without Galactose Surface Decoration
Source abstract
Abstract
Polymeric micelles with and without galactose are synthesized to study liver targeting ability in an orthotopic HCC rat model. Micelles with galactose accumulate more in the healthy liver tissue instead of HCC, while micelles without galactose amass in HCC by the EPR effect. These micelles show great potential as drug delivery carriers to target either the liver or HCC. As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Electrospun Nanofibers in Biomedical Applications · Conducting polymers and applications · biodegradable polymer synthesis and properties
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute of Bioengineering and Nanotechnology (IBN) 31 Biopolis Way, The Nanos, #04–10 138669 Singapore
Department of Biological Sciences National University of Singapore 14 Science Drive 4 117543 Singapore
IBM Almaden Research Center 650 Harry Road San Jose CA 95120 USA
References (22)
Show source-provided references
1. 10.1097/MCG.0b013e3181d46ef210.1097/MCG.0b013e3181d46ef2 ↗
2. 10.2174/13816120677902624510.2174/138161206779026245 ↗
3. 10.2353/ajpath.2010.09013610.2353/ajpath.2010.090136 ↗
4. 10.1002/(SICI)1097-0215(19990517)81:4<519::AID-IJC3>3.0.CO;2-010.1002/(SICI)1097-0215(19990517)81:4<519::AID-IJC3>3.0.CO;2-0 ↗
5. 10.1002/pmic.20090060710.1002/pmic.200900607 ↗
6. 10.1111/j.1872-034X.2008.00387.x10.1111/j.1872-034X.2008.00387.x ↗
7. 10.1038/sj.bjc.669070810.1038/sj.bjc.6690708 ↗
8. 10.1021/bm200685610.1021/bm2006856 ↗
9. 10.1016/j.biomaterials.2012.06.04810.1016/j.biomaterials.2012.06.048 ↗
10. 10.1016/j.jconrel.2005.09.00110.1016/j.jconrel.2005.09.001 ↗
11. 10.1016/S0142-9612(99)00268-910.1016/S0142-9612(99)00268-9 ↗
12. 10.1021/bm060795n10.1021/bm060795n ↗
13. 10.1016/j.actbio.2005.07.00410.1016/j.actbio.2005.07.004 ↗
14. 10.1021/cr068415b10.1021/cr068415b ↗
15. 10.1016/j.biomaterials.2009.12.02210.1016/j.biomaterials.2009.12.022 ↗
16. 10.1016/j.biomaterials.2010.07.01810.1016/j.biomaterials.2010.07.018 ↗
17. 10.1007/s00330-002-1524-x10.1007/s00330-002-1524-x ↗
18. 10.1016/j.biomaterials.2013.01.04210.1016/j.biomaterials.2013.01.042 ↗
19. Moghimi S. M. · Pharmacol. Rev. · 2001 · 53 · 28310.1016/S0031-6997(24)01494-7 ↗
20. 10.1016/j.addr.2010.03.01110.1016/j.addr.2010.03.011 ↗
21. 10.1021/mp800051m10.1021/mp800051m ↗
22. 10.1007/s00705005009510.1007/s007050050095 ↗